Faculty Profiles - NAGAO Shoji

Papers - NAGAO Shoji

Division display 101 - 120 of about 128 ／ All the affair displays >>

MPAが奏功せず腹腔鏡下子宮全摘となった一例治療中の子宮内膜組織診の変化の検討

若橋宣, 浮田真沙世, 中江彩, 小菊愛, 山本香澄, 三輪真唯子, 森本明美, 松村聡子, 市田耕太郎, 須藤保, 長尾昌二, 山口聡, 佐久間淑子, 藤原潔

日本産科婦人科内視鏡学会雑誌 31 ( Suppl.I ) 267 - 267 2015.8

婦人科腫瘍の診断術前検査を用いた子宮体癌後腹膜リンパ節転移の予測

三輪真唯子, 長尾昌二, 小菊愛, 山本香澄, 森本明美, 若橋宣, 市田耕太郎, 須藤保, 山口聡, 藤原潔

日本婦人科腫瘍学会雑誌 33 ( 3 ) 529 - 529 2015.6

当院で経験した外陰癌29症例の臨床的検討

小菊愛, 山本香澄, 三輪真唯子, 森本明美, 若橋宣, 市田耕太郎, 須藤保, 長尾昌二, 山口聡, 藤原潔

日本婦人科腫瘍学会雑誌 33 ( 3 ) 625 - 625 2015.6

子宮頸癌に対する放射線治療後の骨障害に関する後方視的検討

山本香澄, 長尾昌二, 小菊愛, 三輪真唯子, 森本明美, 若橋宣, 市田耕太郎, 須藤保, 山口聡, 藤原潔

日本婦人科腫瘍学会雑誌 33 ( 3 ) 559 - 559 2015.6

当院で経験した外陰癌29症例の臨床的検討

小菊愛, 鈴木陽介, 山本香澄, 三輪真唯子, 森本明美, 若橋宣, 市田耕太郎, 須藤保, 長尾昌二, 山口聡, 藤原潔

産婦人科の進歩 67 ( 2 ) 226 - 226 2015.5

腹腔鏡下子宮全摘術に至ったMPA療法が奏功しなかった子宮内膜異型増殖症の1例

若橋宣, 鈴木陽介, 小菊愛, 山本香澄, 三輪真唯子, 森本明美, 市田耕太郎, 須藤保, 長尾昌二, 山口聡, 佐久間淑子, 藤原潔

産婦人科の進歩 67 ( 2 ) 226 - 226 2015.5

子宮頸部神経内分泌癌の治療戦略

長尾昌二, 小菊愛, 山本香澄, 三輪真唯子, 森本明美, 若橋宣, 市田耕太郎, 須藤保, 山口聡, 藤原潔

日本産科婦人科学会雑誌 67 ( 2 ) 825 - 825 2015.2

妊孕能温存希望のある子宮頸癌I期症例に対するRadical Trachelectomyの治療成績

山本香澄, 山口聡, 小菊愛, 三輪真唯子, 森本明美, 若橋宣, 市田耕太郎, 長尾昌二, 須藤保, 藤原潔

日本産科婦人科学会雑誌 67 ( 2 ) 832 - 832 2015.2

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Reviewed International journal

Kosei Hasegawa, Shoji Nagao, Masanori Yasuda, David Millan, Akila N Viswanathan, Rosalind M Glasspool, Mojgan Devouassoux-Shisheboran, Alan Covens, Domenica Lorusso, Christian Kurzeder, Jae-Weon Kim, Laurence Gladieff, Jane Bryce, Michael Friedlander, Keiichi Fujiwara

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 24 ( 9 Suppl 3 ) S90-5 2014.11

Language：English Publishing type：Research paper (scientific journal)

Clear cell carcinomas of the uterine corpus and cervix are rare gynecological cancers with limited information regarding the pathogenesis and biology. At present, the approach to management is the same as for patients with the more common histological subtypes of endometrioid endometrial cancer and adenocarcinoma of the cervix. Surgical resection is the standard treatment for patients with early-stage disease, but there is no evidence-based approach to direct the management of patients with more advanced-stage disease at presentation or with recurrent disease. We review the epidemiology, pathology, and what is known about both uterine corpus and cervical clear cell cancers and make management recommendations.

DOI： 10.1097/IGC.0000000000000297

PubMed

researchmap

Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer. Reviewed International journal

Shoji Nagao, Tadaaki Nishikawa, Tatsuya Hanaoka, Akira Kurosaki, Norihiro Iwasa, Kosei Hasegawa, Keiichi Fujiwara

Japanese journal of clinical oncology 44 ( 11 ) 1040 - 4 2014.11

Authorship：Lead author Language：English Publishing type：Research paper (scientific journal)

OBJECTIVE: We evaluated the feasibility of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high-risk or recurrent endometrial cancer. METHODS: Women with histologically confirmed FIGO Stages I-II with >1/2 myometrial invasion, Stage III/IV or recurrent endometrial cancer were enrolled. Patients received intravenous doxorubicin (45 mg/m(2)), followed by cisplatin (50 mg/m(2)) on Day 1 and intravenous paclitaxel (160 mg/m(2)) on Day 2. Granisetron (75 µg) was administered depending on neutrophil counts on Days 3 and 8. Treatment was repeated every 21 days for six cycles or until disease progression or unacceptable toxicity. The primary endpoint was the completion rate of the scheduled chemotherapy; secondary endpoints were Grade 3/4 toxicity and response rate in patients with measurable lesions. RESULTS: From September 2010 to December 2012, 35 women, including 7 with FIGO Stage I, 4 with Stage II, 13 with Stage III, 10 with Stage IV and 1 with recurrent endometrial cancer, were enrolled. There were 26 endometrial carcinomas (Grade 1, 16; Grade 2, 6; Grade 3, 4), 4 carcinosarcomas, 2 serous adenocarcinomas, 1 neuroendocrine carcinoma, 1 poorly differentiated carcinoma and 1 mixed carcinoma. Twenty-five patients (71%) completed six chemotherapy cycles. Grade 3/4 hematological toxicities included neutrocytopenia (97%), thrombocytopenia (6%) and anemia (34%). Three patients (9%) experienced neutropenic fever. Grade 3/4 non-hematological toxicities were observed in 13 patients. In 15 patients with evaluable lesions, the response rate was 80%. CONCLUSIONS: Combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection is feasible.

DOI： 10.1093/jjco/hyu124

PubMed

researchmap

術前化学療法を施行した進行卵巣癌における腫瘍減量手術の時期決定に有用な臨床的指標に関する検討

森本明美, 山本香澄, 三輪真唯子, 玉田将, 若橋宣, 市田耕太郎, 須藤保, 長尾昌二, 山口聡, 藤原潔

日本婦人科腫瘍学会雑誌 32 ( 3 ) 503 - 503 2014.6

[II. Future perspectives of intraperitoneal chemotherapy for ovarian cancer].

Keiichi Fujiwara, Shoji Nagao, Akira Kurosaki, Kosei Hasegawa

Gan to kagaku ryoho. Cancer & chemotherapy 41 ( 2 ) 184 - 7 2014.2

当院での卵巣癌肉腫20例の検討

山本香澄, 三輪真唯子, 森本明美, 浮田真沙世, 玉田将, 若橋宣, 市田耕太郎, 須藤保, 長尾昌二, 山口聡, 藤原潔

日本産科婦人科学会雑誌 66 ( 2 ) 628 - 628 2014.2

Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Reviewed International journal

Shoji Nagao, Shin Nishio, Hirofumi Michimae, Hiroshi Tanabe, Satoshi Okada, Takeo Otsuki, Maki Tanioka, Keiichi Fujiwara, Mitsuaki Suzuki, Junzo Kigawa

Gynecologic oncology 131 ( 3 ) 567 - 73 2013.12

Authorship：Lead author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

OBJECTIVE: The concept of "platinum sensitivity" has been widely applied in the management of recurrent ovarian cancer. This study aimed to evaluate the applicability of this concept to recurrent endometrial cancer. PATIENTS AND METHODS: In this multicenter retrospective cohort study, the clinical data of patients with recurrent endometrial cancer, who had a history of receiving first-line platinum-based chemotherapy and who received second-line platinum-based chemotherapy at the time of recurrence between January 2005 and December 2009 were reviewed. RESULTS: A total of 262 patients from 30 centers with initial FIGO stage classifications of I (29), II (23), III (122), and IV (88) were enrolled. In total, 153 endometrioid adenocarcinomas, 34 serous adenocarcinomas, 17 clear cell adenocarcinomas, 36 carcinosarcomas, and 22 "other" tumors were documented. The response rates for patients with platinum-free intervals of <6 months, 6-11 months, 12-23 months, and ≥24 months were 25%, 38%, 61%, and 65%, respectively. The median progression-free survival after second-line platinum-based chemotherapy for patients with platinum-free intervals of <12 months and ≥12 months was 4.4 (95% confidence interval (CI)=3.7-5.8) months and 10.3 (95% CI=8.2-12.6) months, respectively (log-rank P<0.0001), and the median overall survival was 13.8 (95% CI=10.6-18.1) months and 40.9 (95% CI=25.3-54.2) months, respectively (log-rank P<0.0001). CONCLUSION: Platinum-free interval is a predictor of response and survival after second-line platinum-based chemotherapy in patients with recurrent endometrial cancer. The concept of "platinum sensitivity" could be applicable to recurrent endometrial cancer.

DOI： 10.1016/j.ygyno.2013.09.021

PubMed

researchmap

子宮癌術後に尿道周囲に限局し再発した3症例

三輪真唯子, 山本香澄, 森本明美, 玉田将, 浮田真沙世, 若橋宣, 市田耕太郎, 須藤保, 長尾昌二, 山口聡, 藤原潔

日本癌治療学会誌 48 ( 3 ) 2434 - 2434 2013.9

[Intraperitoneal chemotherapy].

Shoji Nagao, Akira Kurosaki, Norihiro Iwasa, Keiichi Fujiwara

Nihon rinsho. Japanese journal of clinical medicine 70 Suppl 4 610 - 6 2012.6

Extrauterine low-grade endometrial stromal sarcomaの1例

堀祐子, 花岡立也, 西川忠曉, 黒崎亮, 大石理恵, 岩佐紀宏, 長谷川幸清, 長尾昌二, 藤原恵一

日本産科婦人科学会雑誌 64 ( 2 ) 648 - 648 2012.2

中腎管遺残過形成を背景に中腎性腺癌が発生し、脱分化を伴って癌肉腫へ移行した子宮頸部癌肉腫の1例

黒崎亮, 長尾昌二, 花岡立也, 西川忠曉, 大石理恵, 堀祐子, 岩佐紀宏, 長谷川幸清, 藤原恵一

日本産科婦人科学会雑誌 64 ( 2 ) 797 - 797 2012.2

子宮頸部明細胞腺癌の4例

西川忠曉, 長尾昌二, 花岡立也, 黒崎亮, 大石理恵, 岩佐紀宏, 長谷川幸清, 藤原恵一

日本産科婦人科学会雑誌 64 ( 2 ) 794 - 794 2012.2

First attempt of large phase III oncology trial using Japanese new trial evaluation system, the evaluation system of investigational medical care Reviewed

Eriko Aotani, Shinobu Kukino, Miwa Nonaka, Shoji Nagao, Keiichi Fujiwara

Japanese Pharmacology and Therapeutics 38 ( 1 ) S59 - S64 2010.7

Language：Japanese Publishing type：Research paper (scientific journal)

Background: This is the first attempt to conduct a large-scale phaseIII oncology trial using the Evaluation System of Investigational Medical Care (ESIMeC). Methods: The study design is a randomized phase II / III trial comparing administration routes of carboplatin either intravenously (IV) or intraperitoneally (IP) in combination with weekly administration of paclitaxel for ovarian cancer patients. Target accrual is 746. Both IP carboplatin and weekly paclitaxel have not been approved for national insurance coverage in Japan. Results: Because of the expensive drug cost, it was first assumed impossible to conduct the trial if the study chair is responsible for purchasing the investigational drugs from the limited research grant or the patients have to pay for the investigational drugs without insurance coverage. Therefore, we negotiated with the pharmaceutical companies including generic makers to supply the investigational drugs with free of charge. The duration from initial consultation to the Ministry of Health, Labor, and Welfare to the finial approval to conduct the trial using ESIMeC was 8 months. Conclusion: The ESIMeC appears to be an efficient system as the official evaluation process of investigator-initiated, non-indication directed clinical trials, which manifestly require quality control of the trials. However, cost coverage for the investigational medicine or technique remains as an important issue to be resolved in the future, especially in large phase III oncology trials.

Scopus

researchmap

　 PREV - NEXT 　

< NAGAO Shoji >

Papers - NAGAO Shoji